Full Press Release Details
Solid Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and 2 Year Efficacy and Safety Data from the Ongoing Phase I II IGNITE DMD Clinical Trial of SGT-001.
SLDB
Solid Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and 2 Year Efficacy and Safety Data from the Ongoing Phase I II IGNITE DMD Clinical Trial of SGT-001
Key Takeaway: Solid Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and 2 Year Efficacy and Safety Data from the Ongoing Phase I II IGNITE DMD Clinical Trial of SGT-001